<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Protein kinase inhibitors; Tyrosine kinase inhibitors; Axitinib; Crizotinib; Dasatinib; Erlotinib; Everolimus; Gefitinib; Imatinib; Lapatinib; Nilotinib; Pazopanib; Ruxolitinib; Sorafenib; Sunitinib; Temsirolimus; Vandetanib; Vemurafenib" /><meta name="IX" content="Protein kinase inhibitors; Tyrosine kinase inhibitors; Axitinib; Crizotinib; Dasatinib; Erlotinib; Everolimus; Gefitinib; Imatinib; Lapatinib; Nilotinib; Pazopanib; Ruxolitinib; Sorafenib; Sunitinib; Temsirolimus; Vandetanib; Vemurafenib" /><title>Protein kinase inhibitors: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5514-protein-kinase-inhibitors.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5514-protein-kinase-inhibitors.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="PHP5514-protein-kinase-inhibitors.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 13 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5180-cytotoxic-drugs.htm">8.1 Cytotoxic drugs</a> &gt; <a href="PHP5425-other-antineoplastic-drugs.htm">8.1.5 Other antineoplastic drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5511-procarbazine.htm" title="Previous: PROCARBAZINE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP18848-axitinib.htm" title="Next: AXITINIB">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="pB"><?highlighter on?><h1>Protein kinase inhibitors</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h3 class="cO">Additional information</h3> <p class="cT"> interactions (<a href="bnf_int1087-protein-kinase-inhibitors.htm">Protein Kinase Inhibitors</a>).</p></div></div><p id="PHP18850"><strong>Axitinib</strong>, a tyrosine kinase inhibitor, is licensed for the treatment of advanced renal cell carcinoma following failure of previous treatment with sunitinib or a cytokine (aldesleukin or interferon alfa).</p><p id="PHP19014"><strong>Crizotinib</strong>, a tyrosine kinase inhibitor, is licensed for previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer.</p><p id="PHP5515"><strong>Dasatinib</strong>, a tyrosine kinase inhibitor, is licensed for the treatment of chronic myeloid leukaemia in those who have resistance to or intolerance of previous therapy, including imatinib. It is also licensed for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in the chronic phase and for acute lymphoblastic leukaemia (Philadelphia chromosome positive) in those who have resistance to or intolerance of previous therapy. </p><p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (April 2007) that the use of dasatinib (<em>Sprycel</em>®) in NHS Scotland is restricted to patients in the chronic phase of chronic myeloid leukaemia.</p><div id="PHP18379" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (April 2012)</h3><p>Standard-dose imatinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia (CML); see also NICE guidance <a title="Imatinib for chronic myeloid leukaemia (October 2003)" href="PHP5514-protein-kinase-inhibitors.htm#PHP18381">Imatinib for chronic myeloid leukaemia (October 2003)</a>.</p><p>Nilotinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive CML if the manufacturer makes nilotinib available with the discount agreed as part of the patient access scheme.</p><p>Dasatinib is <strong>not</strong> recommended for the first-line treatment of chronic phase Philadelphia-chromosome-positive CML</p> <p><a href="http://www.nice.org.uk/TA251">www.nice.org.uk/TA251</a></p></div><div id="PHP18380" class="cI"><p class="cAE">NICE guidance</p> <h3 class="cT">Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (January 2012)</h3><p>Nilotinib is recommended for the treatment of chronic or accelerated phase Philadelphia-chromosome-positive chronic myeloid leukaemia (CML) in adults:</p><ul><li><p>whose CML is resistant to treatment with standard-dose imatinib, <strong>or</strong></p></li><li>  <p>who have imatinib intolerance, <strong>and</strong></p></li><li>  <p>if the manufacturer makes nilotinib available with the discount agreed as part of the patient access scheme.</p></li></ul><p>Dasatinib is <strong>not</strong> recommended for the treatment of chronic, accelerated or blast-crisis phase CML in adults with imatinib intolerance or whose CML is resistant to treatment with standard-dose imatinib.</p><p>High-dose imatinib is <strong>not</strong> recommended for the treatment of chronic, accelerated or blast-crisis phase Philadelphia-chromosome-positive CML that is resistant to standard-dose imatinib.</p> <p><a href="http://www.nice.org.uk/TA241">www.nice.org.uk/TA241</a></p></div><p id="PHP5516"><strong>Erlotinib</strong>, a tyrosine kinase inhibitor, is licensed in combination with gemcitabine for the treatment of metastatic pancreatic cancer. It is also licensed for the treatment of locally advanced or metastatic non-small cell lung cancer after failure of previous chemotherapy and as monotherapy for maintenance treatment of locally advanced or metastatic non-small cell lung cancer with stable disease after four cycles of platinum-based chemotherapy.</p><p>The <em><a title="target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70">Scottish Medicines Consortium</a></em> has advised (May 2006) that erlotinib (<em>Tarceva</em>®) is accepted for restricted use within NHS Scotland for the treatment of locally advanced or metastatic non-small cell lung cancer, after failure of at least one chemotherapy regimen. Erlotinib is restricted to use in patients who would otherwise be eligible for treatment with docetaxel monotherapy. The <a title="NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has also advised (December 2011) that erlotinib (<em>Tarceva</em>®) is accepted for use within NHS Scotland for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.</p><div id="PHP19120" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Erlotinib for non-small-cell lung cancer (November 2008)</h3><p>Erlotinib is recommended, as an alternative to docetaxel, as second-line treatment for locally advanced or metastatic non-small-cell lung cancer after failure of previous chemotherapy, on the basis that it is provided by the manufacturer at an overall treatment cost equal to that of docetaxel. Erlotinib is <strong>not</strong> recommended in patients for whom docetaxel is unsuitable or as third-line treatment after docetaxel.</p><p><a href="http://www.nice.org.uk/TA162">www.nice.org.uk/TA162</a></p></div><div id="PHP19121" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (June 2011)</h3><p>Erlotinib monotherapy is <strong>not</strong> recommended for maintenance treatment in people with locally advanced or metastatic non-small-cell lung cancer who have stable disease after platinum-based first-line chemotherapy.</p><p><a href="http://www.nice.org.uk/TA227">www.nice.org.uk/TA227</a></p></div><div id="PHP18630" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (June 2012)</h3><p>Erlotinib is recommended as an option for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer if:</p><ul><li><p>they test positive for the epidermal growth factor tyrosine kinase (EGFR-TK) mutation <strong>and</strong></p></li><li><p>the manufacturer provides erlotinib at the discounted price agreed under the patient access scheme (as revised in 2012).</p></li></ul><p><a href="http://www.nice.org.uk/TA258">www.nice.org.uk/TA258</a></p></div><p id="PHP5517"><strong>Everolimus</strong>, a protein kinase inhibitor, is licensed for the treatment of advanced renal cell carcinoma when the disease has progressed despite treatment with vascular endothelial growth factor-targeted therapy (see NICE guidance below), and for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin. It is licensed for the treatment of subependymal giant cell astrocytoma associated with tuberous sclerosis complex in patients who require therapeutic intervention but are not amenable to surgery, and for renal angiomyolipoma associated with tuberous sclerosis complex in patients at risk of complications, but who do not require immediate surgery. Everolimus is also licensed for the treatment of hormone-receptor-positive, human epidermal growth factor-2 (HER-2) negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.</p><div id="PHP19122" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Everolimus for the second-line treatment of advanced renal cell carcinoma (April 2011)</h3><p>Everolimus is <strong>not</strong> recommended for the second-line treatment of advanced renal cell carcinoma.</p><p><a href="http://www.nice.org.uk/TA219">www.nice.org.uk/TA219</a></p></div><p id="PHP5518"><strong>Gefitinib</strong>, a tyrosine kinase inhibitor, is licensed for the treatment of locally advanced or metastatic non-small cell lung cancer with activating mutations of epidermal growth factor receptor.</p><div id="PHP19123" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (July 2010)</h3><p>Gefitinib is recommended as an option for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer if the patient tests positive for the epidermal growth receptor tyrosine kinase (EGFR-TK) mutation and the manufacturer provides gefitinib at the fixed price agreed under the patient access scheme.</p><p><a href="http://www.nice.org.uk/TA192">www.nice.org.uk/TA192</a></p></div><p id="PHP5519"><strong>Imatinib</strong>, a tyrosine kinase inhibitor, is licensed for the treatment of newly diagnosed chronic myeloid leukaemia where bone marrow transplantation is not considered first-line treatment, and for chronic myeloid leukaemia in chronic phase after failure of interferon alfa, or in accelerated phase, or in blast crisis (see NICE guidance below). It is also licensed for the treatment of c-kit (CD117)-positive unresectable or metastatic malignant gastro-intestinal stromal tumours (GIST), and as adjuvant treatment following resection of c-kit (CD117)-positive GIST, in patients at significant risk of relapse. Imatinib is licensed for the treatment of newly diagnosed acute lymphoblastic leukaemia in combination with other chemotherapy, and as monotherapy for relapsed or refractory acute lymphoblastic leukaemia. Imatinib is also licensed for the treatment of unresectable dermatofibrosarcoma protuberans and for patients with recurrent or metastatic dermatofibrosarcoma protuberans who cannot have surgery.</p><p>Imatinib is also licensed for the treatment of myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor gene rearrangement and for the treatment of advanced hypereosinophilic syndrome and chronic eosinophilic leukaemia.</p><p>The <em><a title="target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70">Scottish Medicines Consortium</a></em> has advised (March 2002) that imatinib (<em>Glivec</em>®) should be used for chronic myeloid leukaemia only under specialist supervision in accordance with British Society of Haematology guidelines (November 2001). The <a title="NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has also advised (February 2012) that imatinib (<em>Glivec</em>®) is accepted for restricted use within NHS Scotland for the treatment of adult patients who are at significant risk of relapse following resection of a KIT (CD117) positive gastrointestinal stromal tumour (GIST) and who are at high risk of recurrence following complete resection (according to the Armed Forces Institute of Pathology (AFIP) risk criteria).</p><div id="PHP18381" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Imatinib for chronic myeloid leukaemia (October 2003)</h3><p>Imatinib is recommended as first-line treatment for Philadelphia-chromosome-positive chronic myeloid leukaemia in the chronic phase and as an option for patients presenting in the accelerated phase or with blast crisis, provided that imatinib has not been used previously.</p><p>See also NICE guidance <a title="Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (April 2012)" href="PHP5514-protein-kinase-inhibitors.htm#PHP18379">Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (April 2012)</a> and NICE guidance <a title="Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (January 2012)" href="PHP5514-protein-kinase-inhibitors.htm#PHP18380">Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia, and dasatinib and nilotinib for people with CML</a><a title="Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (January 2012)" href="PHP5514-protein-kinase-inhibitors.htm#PHP18380"> for whom treatment of imatinib has failed because of intolerance (January 2012)</a></p><p><a href="http://www.nice.org.uk/TA70">www.nice.org.uk/TA70</a></p></div><div id="PHP19124" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Imatinib for the adjuvant treatment of gastro-intestinal stromal tumours (August 2010)</h3><p>Imatinib is not recommended for the adjuvant treatment of gastro-intestinal stromal tumours after surgery.</p><p><a href="http://www.nice.org.uk/TA196">www.nice.org.uk/TA196</a></p></div><div id="PHP19125" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (October 2004)</h3><p>Imatinib 400 mg daily is recommended as first-line management of KIT (CD117)-positive unresectable or metastatic, or both, gastro-intestinal stromal tumours. Continued therapy is recommended only if a response to initial treatment [as defined by Southwest Oncology Group criteria available at <a href="http://www.nice.org.uk/TA86">www.nice.org.uk/TA86</a>] is achieved within 12 weeks. Patients who have responded should be assessed at 12-week intervals. Discontinue if tumour ceases to respond.</p><p><a href="http://www.nice.org.uk/TA86">www.nice.org.uk/TA86</a></p></div><div id="PHP19126" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (November 2010)</h3><p>Imatinib 600 mg daily or 800 mg daily is not recommended for unresectable or metastatic, or both, gastro-intestinal stromal tumours whose disease has progressed after treatment with imatinib 400 mg daily.</p><p><a href="http://www.nice.org.uk/TA209">www.nice.org.uk/TA209</a></p></div><p id="PHP5520"><strong>Lapatinib</strong>, a tyrosine kinase inhibitor, is licensed for the treatment of advanced or metastatic breast cancer in patients with tumours that overexpress human epidermal growth factor receptor-2 (HER2). It is indicated, in combination with capecitabine, for patients who have had previous treatment with an anthracycline, a taxane, and trastuzumab, or for postmenopausal women in combination with an aromatase inhibitor <a title="BNF:sub-sub-section: Breast cancer" href="PHP5747-breast-cancer.htm">section 8.3.4.1</a>.</p><div id="PHP18572" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (June 2012)</h3><p>Lapatinib or trastuzumab in combination with an aromatase inhibitor is <strong>not</strong> recommended for first-line treatment in postmenopausal women of metastatic hormone-receptor-positive breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2).</p><p>Postmenopausal women currently receiving lapatinib or trastuzumab in combination with an aromatase inhibitor for this indication should have the option to continue treatment until they and their clinician consider it appropriate to stop.</p><p><a href="http://www.nice.org.uk/TA257">www.nice.org.uk/TA257</a></p></div><p id="PHP5521"><strong>Nilotinib</strong>, a tyrosine kinase inhibitor, is licensed for the treatment of newly diagnosed chronic myeloid leukaemia in the chronic phase, and also for patients with chronic or accelerated phase chronic myeloid leukaemia who have resistance to or intolerance of previous therapy, including imatinib.</p><p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (February 2008) that nilotinib (<em>Tasigna</em>®) is accepted for restricted use within NHS Scotland for the treatment of chronic-phase chronic myeloid leukaemia in adults resistant to or intolerant of at least one previous therapy, including imatinib, and (July 2011) for the treatment of adults with newly diagnosed chronic myeloid leukaemia in the chronic phase.</p><div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (April 2012)</h3><p>See <a title="Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (April 2012)" href="PHP5514-protein-kinase-inhibitors.htm#PHP18379">Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (April 2012)</a></p> </div><div class="cI"><p class="cAE">NICE guidance</p> <h3 class="cT">Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (January 2012)</h3><p>See <a title="Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (January 2012)" href="PHP5514-protein-kinase-inhibitors.htm#PHP18380">Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (January 2012)</a></p></div><p id="PHP5522"><strong>Pazopanib</strong>, a tyrosine kinase inhibitor, is licensed for advanced renal cell carcinoma, as first-line treatment and for patients who have had previous treatment with cytokine therapy for advanced disease. It is also licensed for the treatment of selective subtypes of advanced soft tissue sarcoma (consult product literature for details).</p><p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (February 2011) that pazopanib (<em>Votrient</em>®) is accepted for restricted use within NHS Scotland for the first-line treatment of advanced renal cell carcinoma and (December 2012) is <strong>not</strong> recommended for use within NHS Scotland for the treatment of selective subtypes of advanced soft tissue sarcoma in patients who have received prior chemotherapy for metastatic disease, or who have progressed within 12 months after (neo)adjuvant therapy.</p><div id="PHP19127" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Pazopanib for the first-line treatment of advanced renal cell carcinoma (February 2011)</h3><p>Pazopanib is recommended as a first-line treatment option for people with advanced renal cell carcinoma who have <strong>not</strong> received prior cytokine therapy.</p><p><a href="http://www.nice.org.uk/TA215">www.nice.org.uk/TA215</a></p></div><p id="PHP18723"><strong>Ruxolitinib</strong> is a selective inhibitor of the Janus-associated tyrosine kinases JAK1 and JAK2 and is licensed for the treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis.</p><p id="PHP5523"><strong>Sorafenib</strong>, an inhibitor of multiple kinases, is licensed for the treatment of advanced renal cell carcinoma when treatment with interferon alfa or interleukin-2 has failed or is contra-indicated (but see NICE Guidance below). It is also licensed for the treatment of hepatocellular carcinoma.</p><div id="PHP19128" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Sorafenib for the treatment of advanced hepatocellular carcinoma (May 2010)</h3><p>Sorafenib is <strong>not</strong> recommended for the treatment of advanced hepatocellular carcinoma in patients for whom surgical or locoregional therapies have failed or are unsuitable.</p><p><a href="http://www.nice.org.uk/TA189">www.nice.org.uk/TA189</a></p></div><p id="PHP5524"><strong>Sunitinib</strong>, a tyrosine kinase inhibitor, is licensed for the treatment of advanced or metastatic renal cell carcinoma (but see NICE Guidance, below). It is also licensed for the treatment of unresectable or metastatic malignant gastro-intestinal stromal tumours, after failure of imatinib, and for the treatment of unresectable or metastatic pancreatic neuroendocrine tumours.</p><p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (October 2009 and April 2011) that sunitinib (<em>Sutent</em>®) is accepted for restricted use within NHS Scotland for the treatment of unresectable or metastatic malignant gastro-intestinal stromal tumours after failure of imatinib and for unresectable or metastatic pancreatic neuroendocrine tumours.</p><div id="PHP19129" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Sunitinib for advanced or metastatic renal cell carcinoma (March 2009)</h3><p>Sunitinib is recommended as first-line treatment for advanced or metastatic renal cell carcinoma in patients who are suitable for immunotherapy and have an Eastern Cooperative Oncology Group performance status of 0 or 1.</p><p><a href="http://www.nice.org.uk/TA169">www.nice.org.uk/TA169</a></p></div><div id="PHP19130" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Sunitinib for the treatment of gastro-intestinal stromal tumours (September 2009)</h3><p>Sunitinib is recommended as an option for treatment in patients with unresectable or metastatic gastro-intestinal tumours if imatinib treatment has failed because of resistance or intolerance, and the cost of sunitinib for the first treatment cycle is met by the manufacturer.</p><p><a href="http://www.nice.org.uk/TA179">www.nice.org.uk/TA179</a></p></div><div id="PHP5525" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced or metastatic renal cell carcinoma (August 2009)</h3><p>Bevacizumab, sorafenib, and temsirolimus are not recommended as first-line treatments for people with advanced or metastatic renal cell carcinoma.</p><p>Sorafenib and sunitinib are not recommended as second-line treatments for people with advanced or metastatic renal cell carcinoma.</p><p><a href="http://www.nice.org.uk/TA178">www.nice.org.uk/TA178</a></p></div><p id="PHP5526"><strong>Temsirolimus</strong> is a protein kinase inhibitor licensed for the first-line treatment of advanced renal cell carcinoma (see NICE Guidance above), and for the treatment of relapsed or refractory mantle cell lymphoma. Hypersensitivity reactions, including some life-threatening and rare fatal reactions, are associated with temsirolimus therapy, usually during administration of the first dose. Symptoms include flushing, chest pain, dyspnoea, apnoea, hypotension, loss of consciousness, and anaphylaxis. Where possible, patients should receive an intravenous dose of antihistamine 30 minutes before starting the temsirolimus infusion. The infusion may have to be stopped temporarily for the treatment of infusion-related effects—consult product literature for appropriate management. If adverse reactions are not managed with dose delays, a dose reduction should be considered—consult product literature.</p><p id="PHP18391"><strong>Vandetanib</strong>, a tyrosine kinase inhibitor, is licensed for the treatment of aggressive and symptomatic medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.</p><p id="PHP18364"><strong>Vemurafenib</strong>, a BRAF kinase inhibitor, is licensed as a monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma.</p><p>The <a title="NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (August 2012) that vemurafenib (<em>Zelboraf</em>®) is <strong>not</strong> recommended for use within NHS Scotland as monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma.</p><div class="cI" id="PHP19031"><p class="cAE">NICE guidance</p><h3 class="cT">Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma (December 2012)</h3><p>Vemurafenib is recommended as an option for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma only if the manufacturer provides vemurafenib with the discount agreed in the patient access scheme.</p><p><a href="http://www.nice.org.uk/TA269">www.nice.org.uk/TA269</a></p></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP18848-axitinib"><a href="PHP18848-axitinib.htm" title="AXITINIB">AXITINIB</a></li><li id="_PHP18995-crizotinib"><a href="PHP18995-crizotinib.htm" title="CRIZOTINIB">CRIZOTINIB</a></li><li id="_PHP5527-dasatinib"><a href="PHP5527-dasatinib.htm" title="DASATINIB">DASATINIB</a></li><li id="_PHP5529-erlotinib"><a href="PHP5529-erlotinib.htm" title="ERLOTINIB">ERLOTINIB</a></li><li id="_PHP5531-everolimus"><a href="PHP5531-everolimus.htm" title="EVEROLIMUS">EVEROLIMUS</a></li><li id="_PHP5534-gefitinib"><a href="PHP5534-gefitinib.htm" title="GEFITINIB">GEFITINIB</a></li><li id="_PHP5536-imatinib"><a href="PHP5536-imatinib.htm" title="IMATINIB">IMATINIB</a></li><li id="_PHP5538-lapatinib"><a href="PHP5538-lapatinib.htm" title="LAPATINIB">LAPATINIB</a></li><li id="_PHP5540-nilotinib"><a href="PHP5540-nilotinib.htm" title="NILOTINIB">NILOTINIB</a></li><li id="_PHP5542-pazopanib"><a href="PHP5542-pazopanib.htm" title="PAZOPANIB">PAZOPANIB</a></li><li id="_PHP18720-ruxolitinib"><a href="PHP18720-ruxolitinib.htm" title="RUXOLITINIB">RUXOLITINIB</a></li><li id="_PHP5544-sorafenib"><a href="PHP5544-sorafenib.htm" title="SORAFENIB">SORAFENIB</a></li><li id="_PHP5546-sunitinib"><a href="PHP5546-sunitinib.htm" title="SUNITINIB">SUNITINIB</a></li><li id="_PHP5548-temsirolimus"><a href="PHP5548-temsirolimus.htm" title="TEMSIROLIMUS">TEMSIROLIMUS</a></li><li id="_PHP18390-vandetanib"><a href="PHP18390-vandetanib.htm" title="VANDETANIB">VANDETANIB</a></li><li id="_PHP17983-vemurafenib"><a href="PHP17983-vemurafenib.htm" title="VEMURAFENIB">VEMURAFENIB</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5511-procarbazine.htm">Previous: PROCARBAZINE</a> | <a class="top" href="PHP5514-protein-kinase-inhibitors.htm#">Top</a> | <a accesskey="]" href="PHP18848-axitinib.htm">Next: AXITINIB</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>